Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) just unveiled an announcement.
On February 12, 2026, Microbot Medical announced that its LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy in Miami Beach, held February 9–12, 2026. The system, described as the only FDA-cleared, single-use endovascular robot, was highlighted in a town hall on advances in endovascular robotics for its workflow integration and potential to ease operator strain as procedures grow more complex.
Company executives said LIBERTY’s inclusion at ISET underscores growing commercial traction during its limited U.S. market release, which began in late 2025. They reported use across multiple hospitals and specialties, including interventional radiology, oncology, vascular surgery and cardiology, suggesting broad clinical relevance in the peripheral space and setting the stage for a planned full market launch at the Society of Interventional Radiology conference in April 2026.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular interventions, designed for precision, efficiency and safety in vascular navigation.
Average Trading Volume: 1,893,785
Technical Sentiment Signal: Strong Sell
Current Market Cap: $137.7M
Learn more about MBOT stock on TipRanks’ Stock Analysis page.